Postoperative PainPhase 2NCT03695367
Phase 2 Herniorrhaphy Study for Opioid Elimination
A Phase 2 study testing HTX-011, Luer lock applicator and Vial access device in people with Postoperative Pain, run by Heron Therapeutics at 5 sites in United States.
Trial summary
This is a Phase 2, open-label study in subjects undergoing unilateral open inguinal herniorrhaphy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Postoperative Pain
- What is being tested?
- HTX-011, Luer lock applicator and Vial access device
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 63 participants
- Where
- 5 sitesUnited States
- Study dates
- 1 Oct 2018to 15 Dec 2018
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Is scheduled to undergo a unilateral open inguinal herniorrhaphy with mesh under general anesthesia.
- Has an American Society of Anesthesiologists Physical Status of I, II, or III.
- Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.
Who cannot join
- Had any prior inguinal hernia repair except as a child (less than 6 years of age).
- Has a planned concurrent surgical procedure (eg, bilateral herniorrhaphy).
- Has a pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.
- Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
- Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
- Has taken any NSAIDs within least 10 days prior to the scheduled surgery.
Show all 21Show fewer
- Has taken long-acting opioids within 3 days prior to the scheduled surgery.
- Has taken any opioids within 24 hours prior to the scheduled surgery.
- Has been administered bupivacaine within 5 days prior to the scheduled surgery.
- Has been administered any local anesthetic within 72 hours prior to the scheduled surgery.
- Has initiated treatment with study medications within 1 month prior to study drug administration that can impact pain control.
- Has been administered systemic steroids within 5 half-lives or 10 days prior to administration of study drug.
- Has a medical condition such that, in the opinion of the Investigator, participating in the study would pose a health risk to the subject or confound the postoperative assessments.
- As per subject history and/or medical records, has active infection or is currently undergoing treatment for Hepatitis B, Hepatitis C, or human immunodeficiency virus (HIV).
- Has uncontrolled anxiety, psychiatric, or neurological disorder.
- Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
- Has a known or suspected history of drug abuse, a positive drug screen on the day of surgery, or a recent history of alcohol abuse. Note: Subjects with a positive drug screen who are taking an allowed, prescribed medication that is known to result in a positive drug test (eg, amphetamine and dextroamphetamine for attention-deficit/hyperactivity disorder, benzodiazepine for anxiety disorder) may be eligible for participation in the study at the discretion of the Sponsor. Subjects taking any marijuana (medical or recreational) are not allowed to participate in the study.
- Previously participated in an HTX-011 study.
- Received an investigational product or device in a clinical trial within 30 days or within 5 elimination half-lives.
- Has undergone 3 or more surgeries within 12 months.
- Has a body mass index (BMI) >39 kg/m2.
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
United States5 sites
Anaheim Clinical Trials, LLC
Anaheim, California, 92801
JBR Clinical Research
Draper, Utah, 84020
JBR Clinical Research
Murray, Utah, 84107
Lotus Clinical Research, LLC
Pasadena, California, 91105
JBR Clinical Research
Salt Lake City, Utah, 84124
About this study
Official title: A Phase 2, Open-Label Study of HTX 011 in a Multimodal Analgesic Regimen for Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy
This is a Phase 2, open-label study in subjects undergoing unilateral open inguinal herniorrhaphy.
- Conditions
- Postoperative Pain
- Being tested
- HTX-011, Luer lock applicator, Vial access device, Ibuprofen, Acetaminophen
- Keywords
- inguinal hernia, hernia, hernia surgery, postoperative pain, herniorrhaphy
- Medical subject headings
- Pain, Postoperative, Hernia, Inguinal, Hernia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HTX-011Drug
HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation.
Luer lock applicatorDevice
Applicator for instillation.
Vial access deviceDevice
Device for withdrawal of drug product.
IbuprofenDrug
Ibuprofen, 600 mg.
AcetaminophenDrug
Acetaminophen, 1 g.
KetorolacDrug
Intraoperative IV ketorolac.
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1: HTX-011 + MMA Regimen | Experimental | HTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen. Receives: Drug: HTX-011; Device: Luer lock applicator; Device: Vial access device; Drug: Ibuprofen; Drug: Acetaminophen |
| Cohort 2: HTX-011 + MMA Regimen + Ketorolac | Experimental | HTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen and IV ketorolac. Receives: Drug: HTX-011; Device: Luer lock applicator; Device: Vial access device; Drug: Ibuprofen; Drug: Acetaminophen; Drug: Ketorolac |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Subjects Receiving no Opioid Rescue
Measured: 72 hours
Secondary outcomes (4)
Total Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [IV MME])
Measured: 72 hours
Percentge of Subjects Receiving no Opioid Rescue
Measured: 0-24 hours, 24-48 hours, 24-72 hours, 48-72 hours
Percentge of Subjects Receiving no Opioid Rescue
Measured: Day 28
Percentge of Subjects in Severe Pain With Numeric Rating Scale (NRS-R; Windowed Worst Observation Carried Forward) of Pain Intensity Scores >7 on a Scale of 0-10 at Any Point. NRS-R for Pain Where 0 Equals no Pain and 10 Equals Worst Pain Imaginable.
Measured: 72 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Oct 2018
- Study start1 Oct 2018
- Primary completion20 Nov 2018
- Study completion15 Dec 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Postoperative PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 63 participants (actual)
Sponsor and investigators
- Lead sponsor
- Heron Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Neil Singla, MD, Study chair, Lotus Clinical Research, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03695367
- Sponsor's protocol ID
- HTX-011-215
- Status last verified
- Feb 2026
- First submitted
- 1 Oct 2018
- Last updated
- 2 Mar 2026
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Open-Label Study of HTX 011 in a Multimodal Analgesic Regimen for Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy
- ClinicalTrials.gov ID
- NCT03695367
- Acronym / sponsor ID
- HTX-011-215
- Conditions
- Postoperative Pain
- Keywords
- inguinal hernia, hernia, hernia surgery, postoperative pain, herniorrhaphy
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 63 participants (actual)
- Lead sponsor
- Heron TherapeuticsIndustry (pharma, biotech, devices)
- Study start
- 1 Oct 2018 (actual)
- Primary completion
- 20 Nov 2018 (actual)
- Study completion
- 15 Dec 2018 (actual)
- First posted
- 4 Oct 2018 (actual)
- Results
- Posted 2 Jul 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase 2, open-label study in subjects undergoing unilateral open inguinal herniorrhaphy.
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cohort 1: HTX-011 + MMA Regimen | Experimental | Drug: HTX-011, Device: Luer lock applicator, Device: Vial access device, Drug: Ibuprofen, Drug: AcetaminophenHTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen. |
| Cohort 2: HTX-011 + MMA Regimen + Ketorolac | Experimental | Drug: HTX-011, Device: Luer lock applicator, Device: Vial access device, Drug: Ibuprofen, Drug: Acetaminophen, Drug: KetorolacHTX-011 (bupivacaine/meloxicam), 300 mg/9 mg via instillation; non-opioid multimodal analgesic (MMA) regimen and IV ketorolac. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Is scheduled to undergo a unilateral open inguinal herniorrhaphy with mesh under general anesthesia.
- Has an American Society of Anesthesiologists Physical Status of I, II, or III.
- Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant during the study, sterile; or using acceptable contraceptives.
Key exclusion criteria (21 listed)
- Had any prior inguinal hernia repair except as a child (less than 6 years of age).
- Has a planned concurrent surgical procedure (eg, bilateral herniorrhaphy).
- Has a pre-existing concurrent acute or chronic painful physical/restrictive condition expected to require analgesic treatment in the postoperative period for pain.
- Has a contraindication or a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to required study medications.
- Has known or suspected daily use of opioids for 7 or more consecutive days within the previous 6 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HTX-011HTX-011 (bupivacaine/meloxicam), 300 mg/ 9 mg via instillation. | Drug | Cohort 1: HTX-011 + MMA Regimen, Cohort 2: HTX-011 + MMA Regimen + Ketorolac |
| Luer lock applicatorApplicator for instillation. | Device | Cohort 1: HTX-011 + MMA Regimen, Cohort 2: HTX-011 + MMA Regimen + Ketorolac |
| Vial access deviceDevice for withdrawal of drug product. | Device | Cohort 1: HTX-011 + MMA Regimen, Cohort 2: HTX-011 + MMA Regimen + Ketorolac |
| IbuprofenIbuprofen, 600 mg. | Drug | Cohort 1: HTX-011 + MMA Regimen, Cohort 2: HTX-011 + MMA Regimen + Ketorolac |
| AcetaminophenAcetaminophen, 1 g. | Drug | Cohort 1: HTX-011 + MMA Regimen, Cohort 2: HTX-011 + MMA Regimen + Ketorolac |
| KetorolacIntraoperative IV ketorolac. | Drug | Cohort 2: HTX-011 + MMA Regimen + Ketorolac |
Primary outcome
Percentage of Subjects Receiving no Opioid Rescue
Time frame: 72 hours
4 secondary outcomes
Total Postoperative Opioid Consumption (in IV Morphine Milligram Equivalents [IV MME])
Time frame: 72 hours
Percentge of Subjects Receiving no Opioid Rescue
Time frame: 0-24 hours, 24-48 hours, 24-72 hours, 48-72 hours
Percentge of Subjects Receiving no Opioid Rescue
Time frame: Day 28
Percentge of Subjects in Severe Pain With Numeric Rating Scale (NRS-R; Windowed Worst Observation Carried Forward) of Pain Intensity Scores >7 on a Scale of 0-10 at Any Point. NRS-R for Pain Where 0 Equals no Pain and 10 Equals Worst Pain Imaginable.
Time frame: 72 hours
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Postoperative Pain
Active, not recruiting
Dance Study for Post-surgical Pain in Breast Cancer Survivors
Breast Cancer, Survivorship
RecruitingPhase 2/3
Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in Children
Pain, Postoperative
Not yet recruitingPhase 3
Extended Post-Operative Oral Tranexamic Acid Dosing After ACL Reconstruction
Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture
Active, not recruiting
Pivotal Study on the NOVABLOC System for Patients Undergoing Primary Total Knee Arthroplasty
Pain
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Neil Singla, MD study chair
Lotus Clinical Research, LLC
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing HTX-011, Luer lock applicator and Vial access device in people with Postoperative Pain, run by Heron Therapeutics at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 2 Jul 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Subjects Receiving no Opioid Rescue (time frame: 72 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.